{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/gout/diagnosis/investigations/","result":{"pageContext":{"chapter":{"id":"5a86623b-b32c-5e12-b9fe-b1b5a1f7e58f","slug":"investigations","fullItemName":"Investigations","depth":2,"htmlHeader":"<!-- begin field 43d094f2-0f77-4bde-a863-a87700a460cc --><h2>What investigations should I consider?</h2><!-- end field 43d094f2-0f77-4bde-a863-a87700a460cc -->","summary":"","htmlStringContent":"<!-- begin item a506ee05-f16e-4f8c-a200-a87700a455a0 --><!-- begin field 2ab9fb87-297d-4291-90ac-a87700a460cc --><ul><li><strong>No initial investigations are required</strong> when managing people with typical gout-like symptoms if there is no suspicion of other conditions, such as septic arthritis.</li><li>However, the following tests may be considered as part of ongoing follow up of people with gout-like symptoms:<ul><li><strong>Joint fluid microscopy and culture:</strong><ul><li>A definitive diagnosis of gout can be made if urate crystals are observed in synovial fluid or tophi.</li><li>However, aspiration of joint fluid is not generally indicated unless the diagnosis of gout is in doubt or <a class=\"topic-reference internal-reference\" href=\"/topics/gout/diagnosis/differential-diagnosis/\">septic arthritis</a> is suspected.</li><li>It should only be carried out by an experienced clinician.</li></ul></li><li><strong>Serum uric acid (SUA) </strong>is usually measured 4–6 weeks after an acute attack of gout to confirm hyperuricaemia:<ul><li>The formation and deposition of monosodium urate crystals occur when urate levels are persistently above 380 micromol/L.</li><li>Hyperuricaemia may be present without gout. The presence of hyperuricaemia does not equate with a diagnosis of gout, as most people with hyperuricaemia do not develop gout.</li><li>Gout may be present without hyperuricaemia and a normal level of urate does not exclude the diagnosis. Normal levels are often found during an acute flare of gout, when plasma urate levels may fall to normal.</li></ul></li><li><strong>Joint X-ray:</strong><ul><li>Plain radiographs are often normal.</li><li>Non specific soft tissue swelling and subcortical cysts may be present.</li><li>Advanced disease may demonstrate bone erosion.</li></ul></li></ul></li><li><strong>Screen for cardiovascular risk factors and renal disease,</strong> if a clinical diagnosis of gout is made - assess cardiovascular risk and any concomitant renal disease.</li></ul><!-- end field 2ab9fb87-297d-4291-90ac-a87700a460cc --><!-- end item a506ee05-f16e-4f8c-a200-a87700a455a0 -->","topic":{"id":"7ec7842e-cb8a-5712-bb55-65480a391cb5","topicId":"b578fac4-ab4b-4d7b-9df9-2136b4d90e75","topicName":"Gout","slug":"gout","lastRevised":"Last revised in February 2018","chapters":[{"id":"2e71494e-f9a3-5368-8903-3d2121329748","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"738bb44e-1a50-5bc5-8df4-83ac66475493","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"69338c48-0d43-5ae0-9591-5ef289880366","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"0f7680ff-9a88-520a-b2b5-1ff130dfa69b","slug":"changes","fullItemName":"Changes"},{"id":"ae66c6f1-78f9-5532-b310-9d6957882c0c","slug":"update","fullItemName":"Update"}]},{"id":"5de6e4cf-e0c8-56e2-a357-3d063b324cd0","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"86664a1d-e3e5-58c9-957b-56affa17f103","slug":"goals","fullItemName":"Goals"},{"id":"39593d8e-f904-5b99-80e9-e619caf1ec37","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ca59f248-a0b2-5f6c-bfcf-2333dc94f1d9","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"57ca55f4-826e-5832-85a7-dd89f3486be2","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"621c09b7-b5e8-593b-aeb2-fc4a86b884c8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"b39fbed2-7c0d-5440-a769-bab311a7b4d2","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"362edeaf-2f90-506d-b203-f5dbbbfb5835","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a8de4056-6ec0-59ff-911b-561bf7fdb32d","slug":"definition","fullItemName":"Definition"},{"id":"45a8241d-2a2d-5a48-a6d6-2b5ebe02ec27","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"92d229bf-8656-5cfa-aecc-9c069389300f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"79d3b1c2-8d49-55be-99af-41b37c84d582","slug":"complications","fullItemName":"Complications"},{"id":"27dd91cd-92bb-5c2d-8fe8-a184bffce6e7","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"ca0e383b-327b-58c2-adb4-6c5081b6fd8e","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ddea0193-0c14-53db-8e1e-2e71f514988e","slug":"assessment","fullItemName":"Assessment"},{"id":"5a86623b-b32c-5e12-b9fe-b1b5a1f7e58f","slug":"investigations","fullItemName":"Investigations"},{"id":"42a5d4a2-b908-5027-8fb8-f5f336db4c7e","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"5a915955-8e0e-54ae-a1cc-f5875d84d2a2","fullItemName":"Management","slug":"management","subChapters":[{"id":"8a8b4d2a-4efb-5bef-9780-70dc540d41bd","slug":"acute-gout","fullItemName":"Scenario: Acute gout"},{"id":"98793041-11dd-5159-a376-82f5440ee713","slug":"preventing-gout","fullItemName":"Scenario: Preventing gout"}]},{"id":"050e571e-a7a5-5659-9790-2daf0b56580a","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"e7cfef3f-4ab1-5d17-8300-30e91a70eb96","slug":"nsaids","fullItemName":"NSAIDs"},{"id":"cadf7df3-5301-560b-a8ff-e85cfee9ba7c","slug":"colchicine","fullItemName":"Colchicine"},{"id":"60f4beab-f8fc-50e5-8ed9-5073dd8533ec","slug":"corticosteroids","fullItemName":"Corticosteroids"},{"id":"2d2fee49-9ad0-5f0a-9ef1-f253794ed2c7","slug":"allopurinol","fullItemName":"Allopurinol"},{"id":"9830ccbd-f551-5585-a69a-4674759f70cd","slug":"febuxostat","fullItemName":"Febuxostat"},{"id":"ff3edf82-1b21-591c-a8a5-a3b40e7386a5","slug":"paracetamol","fullItemName":"Paracetamol"}]},{"id":"776d98f0-f8da-57c2-983e-1291ac67b761","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[{"id":"71a86333-9110-5847-a2c2-eabf7903c269","slug":"application-of-an-ice-pack","fullItemName":"Application of an ice pack"},{"id":"25688946-80c0-52ab-a32d-99ccab4d738c","slug":"nsaids","fullItemName":"NSAIDs"},{"id":"2921e0f0-467f-5231-87d0-9fed766653ee","slug":"oral-colchicine","fullItemName":"Oral colchicine"},{"id":"09bbf9d4-fe62-5ae1-bc49-f2fede12f711","slug":"corticosteroids","fullItemName":"Corticosteroids"},{"id":"409d2bc0-16d2-5104-8857-eeb5db2a1ecc","slug":"dietary-measures","fullItemName":"Dietary measures"},{"id":"08526f72-ca5a-50db-94b6-3380365360fd","slug":"colchicine-to-prevent-recurrent-gout","fullItemName":"Colchicine to prevent recurrent gout"},{"id":"a53517a7-6d7e-5d2f-886d-e2a3f1bc27b1","slug":"urate-lowering-drugs-in-prevention","fullItemName":"Urate-lowering drugs in prevention"}]},{"id":"f83d98a9-6ce1-50d4-92ad-dd354662a444","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"568c43a6-b0d8-546e-84d2-45781ce305cc","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"5b7cac11-c21d-59fc-83d9-bf16d0d3ab0b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"0e4d0013-b7bc-5179-ac55-8104dec2762c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d75afbe0-7c3d-504e-b369-e56eac297bad","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"45249d1d-8c92-5402-b4f3-108a8a39d94f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"44f1a411-2cf4-55e8-b5e8-266cd568655e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"ca0e383b-327b-58c2-adb4-6c5081b6fd8e","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"54f4cce3-c920-5f9f-b5e3-f89127770763","slug":"basis-for-recommendation-11d","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field c12b4a83-1164-4268-959a-a8a900a9c141 --><h3>Basis for recommendation</h3><!-- end field c12b4a83-1164-4268-959a-a8a900a9c141 -->","summary":null,"htmlStringContent":"<!-- begin item 11de356f-8c57-4bfd-95b3-a8a900a9c0d5 --><!-- begin field f7805d6a-5d51-4785-b472-a8a900a9c141 --><p>The recommendations on investigations to consider in a person with suspected gout are based on expert opinion from a guideline on the diagnosis of acute gout produced by the American College of Physicians [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Qaseem, 2017</a>], an Australian/New Zealand guideline on the diagnosis and management of gout [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Graf, 2015</a>], and review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Roddy, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Dalbeth, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Dalbeth, 2016</a>].</p><ul><li><strong>Fluid microscopy</strong><ul><li>The American College of Physicians advise that although synovial fluid analysis is the gold-standard for gout diagnosis, it may be impractical in primary care and should generally be reserved for when thought necessary to make a diagnosis, particularly in people with clinical ambiguity or the possibility of infection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Qaseem, 2017</a>].</li><li>Multinational guidelines recommend that although there is strong consensus amongst experts that the identification of crystals is required for definitive diagnosis, it may be difficult in some settings and if not possible a diagnosis of gout can be supported by classical clinical features or imaging findings [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Sivera, 2014</a>].</li><li>No randomized controlled trial (RCT) has studied the effect on clinical outcomes of testing for urate crystals in synovial fluid or tophi. The test can have false positives and false negatives, and the quality of the test depends on the quality of both the laboratory providing the test and the specimen sent for testing [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Schlesinger and Schumacher, 2004</a>].</li></ul></li><li><strong>Serum uric acid (SUA)</strong><ul><li>The recommendation to measure SUA is extrapolated from an algorithm for managing acute gout developed by the British Society for Rheumatology (BSR) which recommends review and measurement of SUA 4-6 weeks following an acute attack [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Hui, 2017</a>]. </li><li>Although SUA measurement is not generally required to make a diagnosis, it can be used to guide urate-lowering therapy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Schlesinger and Schumacher, 2004</a>].</li></ul></li><li><strong>Screening for cardiovascular risk factors and renal disease</strong><ul><li>The recommendation to screen for cardiovascular risk factors and renal disease is consistent with guidelines from the British Society for Rheumatology and is based on evidence that gout is an independent risk factor for renal disease and coronary heart disease mortality [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Hui, 2017</a>].</li></ul></li></ul><!-- end field f7805d6a-5d51-4785-b472-a8a900a9c141 --><!-- end item 11de356f-8c57-4bfd-95b3-a8a900a9c0d5 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}